Beat Neuenschwander

发表

Using phase II data for the analysis of phase III studies: An application in rare diseases

Tim Friede, Christian Röver, Simon Wandel, 2016, Clinical trials.

A proof of concept phase II non‐inferiority criterion

Michael Branson, Beat Neuenschwander, Nicolas Rouyrre, 2011, Statistics in medicine.

Predictive Evidence Threshold Scaling: Does the Evidence Meet a Confirmatory Standard?

Michael Branson, Satrajit Roychoudhury, Beat Neuenschwander, 2018 .

Critical aspects of the Bayesian approach to phase I cancer trials

Michael Branson, Beat Neuenschwander, Thomas Gsponer, 2008, Statistics in medicine.

Discussion of the article by Trippa, Rosner, and Müller on Bayesian enrichment strategies for randomized discontinuation trials.

Heinz Schmidli, Beat Neuenschwander, B. Neuenschwander, 2012, Biometrics.

Bayesian models for subgroup analysis in clinical trials

Michael Branson, Beat Neuenschwander, Amy Racine, 2011, Clinical trials.

A note on the power prior

Michael Branson, David J Spiegelhalter, Beat Neuenschwander, 2009, Statistics in medicine.

Use of Historical Data

Heinz Schmidli, Simon Wandel, Beat Neuenschwander, 2016, Bayesian Methods in Pharmaceutical Research.

Beyond p-values: A phase II dual-criterion design with statistical significance and clinical relevance

Satrajit Roychoudhury, Beat Neuenschwander, Nicolas Scheuer, 2018, Clinical trials.

On the Use of Co-Data in Clinical Trials

Heinz Schmidli, Satrajit Roychoudhury, Beat Neuenschwander, 2016 .

Robust exchangeability designs for early phase clinical trials with multiple strata

Satrajit Roychoudhury, Simon Wandel, Beat Neuenschwander, 2016, Pharmaceutical statistics.

Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials

Heinz Schmidli, Tim Friede, Beat Neuenschwander, 2017, Comput. Stat. Data Anal..

Modeling Missingness for Time-to-Event Data: A Case Study in Osteoporosis

Michael Branson, Beat Neuenschwander, 2004, Journal of biopharmaceutical statistics.

Bayesian Approach for Multi-strata Dose-finding Studies in Oncology

Tomoyuki Kakizume, Satrajit Roychoudhury, Simon Wandel, 2014 .

The Predictive Individual Effect for Survival Data

Satrajit Roychoudhury, Simon Wandel, Beat Neuenschwander, 2021, Therapeutic Innovation & Regulatory Science.

Use of historical control data for assessing treatment effects in clinical trials

Fang Chen, Satrajit Roychoudhury, Beat Neuenschwander, 2014, Pharmaceutical statistics.

Ontogeny and Individual Variation: Analysis of Patterned Covariance Matrices with Common Principal Components

Beat Neuenschwander, Bernard D. Flury, Christian Peter Klingenberg, 1996 .

A Bayesian Industry Approach to Phase I Combination Trials in Oncology

Satrajit Roychoudhury, Simon Wandel, Beat Neuenschwander, 2014 .

The network meta-analytic-predictive approach to non-inferiority trials

Heinz Schmidli, Simon Wandel, Beat Neuenschwander, 2013, Statistical methods in medical research.

Using historical control information for the design and analysis of clinical trials with overdispersed count data

Heinz Schmidli, Beat Neuenschwander, Sandro Gsteiger, 2013, Statistics in medicine.

Common Principal Components for Dependent Random Vectors

Beat Neuenschwander, Bernard D. Flury, 2000 .

Common canonical variates

Beat Neuenschwander, Bernard D. Flury, 1995 .

Meta‐analysis of few small studies in orphan diseases

Tim Friede, Christian Röver, Simon Wandel, 2016, Research synthesis methods.

Meta‐analysis of two studies in the presence of heterogeneity with applications in rare diseases

Tim Friede, Christian Röver, Simon Wandel, 2016, Biometrical journal. Biometrische Zeitschrift.

A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates

Michael Branson, Beat Neuenschwander, M. Branson, 2009, Journal of biopharmaceutical statistics.